Evogene Reports Second Quarter 2020 Financial Results

On August 5, 2020 Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, reported its financial results for the second quarter ended June 30, 2020 (Press release, Evogene, AUG 5, 2020, View Source [SID1234563212]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ofer Haviv, Evogene’s President and CEO, stated: "During the second quarter the company announced its new branding, which marks the conclusion to the strategic change the company has been focused on over the past years. With this strategic change, we are aiming to apply our world leading computational biology capabilities to important new market areas in human health and in agriculture. I would like to encourage you to read the press release the company issued regarding the strategic change and rebranding, which can be found on Evogene’s revised website. The Evogene group (consisting of Evogene and its subsidiaries) is continuing to make substantial progress towards its 2020 targets.

"In parallel to the support Evogene provides its subsidiaries, we continue to develop our technological solutions in order to advance our capabilities and expand into new market segments. To that end, during this second quarter, Evogene announced its participation in the CRISPR-IL consortium to provide an end-to-end artificial intelligence system for genome-editing. The consortium is supported by the Israeli Innovation Authority as part of its Bio-Convergence Program and includes 21 industry and academic leaders in the artificial intelligence and genome editing space. Evogene’s Chief Scientific Officer, Dr. Eyal Emmanuel, serves as the chairman of the consortium. Genome editing is a tool that enables genetic changes in a method that may not be considered as GMO (genetically modified organism), and we believe that this revolutionary technology may be a breakthrough for the agricultural market in terms of consumer acceptance. Moreover, this technology has the potential to revolutionize a wide range of life-science based industries," continued Mr. Haviv.

Milestones in the second half of 2020:

AgPlenus (wholly owned subsidiary focused on ag-chemicals)

Herbicide program – reach a ‘Lead’

Achieving a "Lead" phase indicates that a certain family of chemical compounds has shown efficacy in killing weeds in a series of different trials and finally also in commercial application rates in field trials. Reaching the development phase of a "Lead" is a significant and important stage in developing a Herbicide product. AgPlenus is now initiating field trials for its leading candidate in the herbicide program, with results expected by the end of 2020. The family of chemical compounds, expected to undergo these field trials, was discovered and optimized using Evogene’s ChemPass AI solution. In addition, this family of chemical compounds has been proven to work through a new mode-of-action that targets a protein that does not exist in humans, indicating, what we believe to be potential for a high safety profile. A safe, new mode-of-action herbicide is one of the most desired products in the ag-chemical industry, due growing weed resistance to existing commercial products.

Biomica (subsidiary focused on human-microbiome based therapeutics)

Immuno-oncology program – results in extended pre-clinical study

Immune checkpoint inhibitors immunotherapy is considered one of the most effective treatments today for various types of cancer. However, these types of therapies seem to be effective only in a fraction of patients[1]. It has been observed in medical studies[2] that fecal microbiota transplants (FMT), altering the patient’s gut microbiome, have the potential to improve the response rates to immunotherapy. Through the use of Evogene’s MicroBoost AI solution, Biomica is discovering and developing novel microbiome-based drug products to enhance the efficacy of immunotherapy with initial focus on lung cancer. In 2019, preliminary results in animal studies exhibited improved anti-tumor activity following treatment with Biomica’s leading microbial consortia BMC121 and BMC127 in combination with immune checkpoint inhibitors. This year, Biomica initiated extended pre-clinical studies and expects results from this study in the second half of 2020. Positive results will be a significant milestone supporting Biomica to move forward towards the anticipated first in man proof of concept clinical trials expected to be initiated in 2021.

Canonic (wholly owned subsidiary focused on medical cannabis)

MetaYield products – demonstrate yield improvement in cannabis lines

The first product line Canonic is focusing on is MetaYield, a product with stable and improved yield profile for medical cannabis products. An important milestone towards this product is to demonstrate significant yield improvement in a broad greenhouse assay. Canonic aims to reach this milestone by the end of 2020, through cultivation, and by utilizing, Evogene’s GeneRator AI solution. Achieving this milestone is expected to provide the unique genomic composition of the MetaYield product line, targeted to be commercialized in 2022.

Engagement with commercial partners for cultivation and production

Canonic is focused on developing unique medical cannabis products, harnessing the power of plant genomics. While the company intends to internally conduct all the activity related to the development of the unique cannabis varieties, the cultivation and production are expected to be conducted through third parties. Canonic has already engaged in framework agreements with several cultivation and production partners in Israel and in Europe, creating the infrastructure for the company’s go-to-market plan. Canonic aims to sign a definitive agreement with such a partner during the second half of 2020, to support the commercialization of MetaYield products, expected in 2022.

Lavie Bio (subsidiary focused on ag-biologicals)

Spring wheat bio-stimulant program – phase advancement and file for registration

Spring wheat bio-stimulant LAV-211 is the most advanced product under development in Lavie Bio’s development pipeline. LAV-211 was discovered and optimized using Evogene’s MicroBoost AI solution, and has shown promising results over several years in diverse locations. LAV-211 is currently being tested in North America with advanced product formulations. Results from these field trials are expected during the second half of 2020. Positive results in these field trials are the milestone required for the company to file for registration for LAV-211, in order to allow the expected commercialization in 2022.

Bio-pesticide program – phase advancement

In its bio-pesticide pipeline, one of Lavie Bio’s leading products is a bio-fungicide for Botrytis and Downy Mildew, where the main commercial application is currently vineyards with the potential to expand to numerous other crops. Lavie Bio is currently testing its product candidate in vineyards in Europe and the United States and expects to share the results of these trials in the coming months. Increasing regulation pressure regarding the use of chemical pesticides, especially in Europe, creates a significant commercial opportunity for an effective bio-fungicide product, such as the bio-fungicide Lavie Bio is currently testing.

Mr. Haviv continued: "I would also like to update that in spite of the ongoing COVID-19 pandemic, the company has resumed full activity and that the company and its employees are working in compliance with the restrictions and guidelines provided by the Israeli health authorities and other applicable governmental authorities and will continue to do so.

"To summarize, we are extremely pleased by the accelerating rate of the Evogene group’s product oriented achievements – both with respect to the multiple individual product potentials, and with respect to this clear demonstration of the broad applicability and powerful competitive advantages of our technology. We are confident that as our subsidiaries continue to execute and their initial products move closer to commercialization, we will be able to further maximize shareholder value and demonstrate our true significance to the scientific and investment communities. Of course, we greatly appreciate the continuing support of our loyal shareholder base," Mr. Haviv concluded.

Consolidated financial results for the quarter ending June 30, 2020:

Cash position: As of June 30, 2020, Evogene had approximately $38.1 million in consolidated net cash, cash related accounts and short-term bank deposits. Approximately $15.2 million of Evogene’s consolidated cash is attributed to its subsidiary, Lavie Bio.

During the first half of 2020, the company’s consolidated cash usage amounted to $8.8 million. Excluding the cash usage of Lavie Bio, the company’s cash usage amounted to $6.3 million during the first half of 2020. During the second quarter of 2020, the company’s consolidated cash usage amounted to $2.5 million. Excluding the cash usage of Lavie Bio, the company’s cash usage amounted to $1.7 million during the second quarter of 2020.

The company’s low burn rate during the second quarter of 2020 is attributed to the following:

(i) Certain measures the company took to mitigate the impact of the COVID-19 pandemic on the Company, including a temporary reduction in salary-based expenditure and a cut back in secondary activities,

(ii) Funds received attributed to the collaboration agreement AgPlenus entered with Corteva during the first quarter of the year, and

(iii) Grant received attributed to the ongoing Phenomics consortium.

For the full year of 2020, the company estimates that its cash usage, excluding cash usage of Lavie Bio, will be within the range of $13-15 million.

Evogene does not have bank debt.

Revenues for the second quarter of 2020 were approximately $0.3 million in comparison to approximately $0.2 million in the same period the previous year. Revenues primarily consist of third-party research and development payments. These revenues represent R&D cost reimbursement and milestone payments under our various collaboration agreements. The majority of these agreements also provide for royalties or other forms of revenue sharing from successfully developed products.

R&D expenses for the second quarter of 2020 were approximately $3.9 million (including a non-cash expense of $0.5 million for amortization of share-based compensation), in comparison to approximately $3.5 million (including a non-cash expense of $0.1 million for amortization of share-based compensation) in the second quarter of 2019. While the actual R&D expenses remained stable from quarter to quarter, R&D expenses attributed to Lavie Bio increased, due to an increase in downstream development activities, which were offset by a reduction in other secondary activities, as mentioned above.

Business Development (BD) expenses for the second quarter of 2020 were approximately $0.5 million, in comparison to $0.5 million in the second quarter of 2019.

G&A expenses for the second quarter of 2020 were approximately $1.1 million, in comparison to approximately $0.8 million in the second quarter of 2019. Despite a temporary reduction in salary-based expenditure during the second quarter of 2020, there was an increase in general and administrative expenses mostly attributed to an increase in the cost of the company’s D&O insurance.

Operating loss for the second quarter of 2020 was approximately $5.2 million (including a non-cash expense of $0.9 million for amortization of share-based compensation), in comparison to approximately $4.7 million (including a non-cash expense of $0.2 million for amortization of share-based compensation) in the second quarter of 2019.

Net financing income for the second quarter of 2020 was approximately $0.4 million in comparison to net financing income of approximately $0.6 million in the second quarter of 2019.

Loss for the second quarter of 2020 was approximately $4.8 million, in comparison to a loss of approximately $4.1 million during second quarter of 2019.

[1] View Source
View Source

[2] Baruch E.N et al., (2019) Fecal microbiota transplantation (FMT) and re-induction of anti-PD-1 therapy in refractory metastatic melanoma patients – preliminary results from a phase I clinical trial. AACR (Free AACR Whitepaper); Cancer Res 2019;79(13 Suppl):Abstract nr CT042.

Conference Call & Webcast Details:

Date: August 5, 2020
Time: 9:00am EST; 16:00 Israel time
Dial-in: 1-888-668-9141 toll free from the United States, or +972-3-918-0609 internationally
Webcast: Available at www.evogene.com.

You may submit a question for management to address during the call until 8:00 am EST; 15:00 Israel time to [email protected].

Replay Information: A replay of the conference call will be available approximately three hours following the completion of the call.

To access the replay, please dial 1-888-326-9310 toll free from the United States, or +972-3-925-5904 internationally. The replay will be accessible through August 7, 2020, and an archive of the webcast will be available on the company’s website for the following 30 days.

10-Q – Quarterly report [Sections 13 or 15(d)]

Merck & Co has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

10-Q – Quarterly report [Sections 13 or 15(d)]

Regeneron has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

INmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business Update

On August 5, 2020 INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), an immunology company developing treatments that harness the patient’s innate immune system to fight disease reported its financial results for the second quarter ended June 30, 2020 and is providing a business update (Press release, INmune Bio, AUG 5, 2020, View Source [SID1234563115]). INmune Bio will hold a conference call today at 4:30 PM Eastern Time. To participate in the call, please dial 415-226-5355 five minutes before the scheduled time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In the second quarter, and year to date, INmune Bio continued to progress forward with both of our clinical platforms," stated RJ Tesi, M.D., Chief Executive Officer of INmune Bio. "We announced interim Phase Ib data demonstrating that our Alzheimer’s Disease candidate, XPro1595, can reduce neuroinflammation. Our progress with XPro1595 supports our overall strategy to create platforms of therapeutics, based on reducing inflammation by targeting the innate immune system to fight disease. We are planning a number of programs employing this approach in NASH, MUC4 expressing HER2+ cancer, ALS and complications of cytokine storm caused by COVID-19. With the Natural Killer Priming platform, we anticipate INKmune Phase I in high-risk MDS to start the second half of this year."

Q2 2020 and Recent Corporate Highlights

DN-TNF Platform Highlights:

●Announced interim Phase Ib data demonstrating that XPro1595 decreases neuroinflammation in patients with Alzheimer’s Disease – XPro1595 reduced neuroinflammation by 40.6% in a white matter tract important for learning and memory.
●Announced combination therapy of Lapatinib with INB03 may be used to overcome resistance to trastuzumab in women with MUC4+/HER2+ breast cancer. This work was presented at the AACR (Free AACR Whitepaper) 2020 by Dr. Roxana Schillaci and may form the basis for a Phase II program in patients with MUC4 expressing HER2+ cancer.

●Initiated a clinical program to test targeting soluble TNF (Quellor), one of the key components of the cytokine storm, using our TNF Inhibitor (DN-TNF) Platform to prevent complications of COVID-19 infection.
●Frontiers in Oncology published an invited entitled Tumor Necrosis Factor α Blockade: an Opportunity to Tackle Breast Cancer by Prof. Roxana Schillaci, a leader in the field of TNF in cancer.

NK Priming Platform Highlights:

●Received regulatory clearance from UK MHRA to initiate a Phase I Trial of INKmune in patients with high-risk MDS – study will be the first-in man trial for INKmune – a novel therapy to prime the patient’s own NK cells to attack their cancer.

●Announced allowance of U.S. Patent covering method for treating cancer by in-vivo priming of natural killer cells.
●Received notice of allowance in counterpart patent in Australia covering method for treating cancer by in-vivo priming of natural killer cells.
●Announced publication of a review article: Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer in the journal Stem Cells Translational Medicine by Prof. Mark Lowdell, Co-Founder and CSO of INmune Bio, Inc. The article reviews the potential of harnessing cells of the innate immune system to treat cancer.

Financial Highlights:

●Closed a $25 million gross proceeds public offering of common stock, including full exercise of Underwriters’ Over-Allotment Option resulting in net proceeds of approximately $23.1 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Upcoming Milestones:

●Report additional data on Phase 1b XPro1595 in Alzheimer’s Disease in 2H 2020.
●Enroll first patient in Phase II Quellor program, targeting COVID-19 patients with immune mediated complications from COVID-19.

●Enroll first patient in Phase I INKmune in High Risk MDS cancer, expected 2H20.
●Enroll first patient in Phase I INKmune in Ovarian cancer, expected mid-2021.

Financial Results for the Second Quarter Ended June 30, 2020:

Net loss attributable to common stockholders for the second quarter ended June 30, 2020 was $2.1 million, compared to $0.4 million for the quarter ended June 30, 2019.

Research and development expense totaled approximately $0.9 million for the second quarter ended June 30, 2020, compared to approximately $0.6 million during the second quarter ended June 30, 2019.

General and administrative expense was approximately $1.2 million for the quarter ended June 30, 2020, compared to approximately $1.3 million during the second quarter ended June 30, 2019.

As of June 30, 2020, the Company had cash and cash equivalents of approximately $4.8 million with no debt. Subsequent to the quarter end, INmune Bio closed a $25 million gross proceeds public offering of common stock resulting in net proceeds of approximately $23.1 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.

As of August 5, 2020, the Company had approximately 13.4 million common shares outstanding.

Earnings Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call

ARC Therapeutics Launches to Develop Novel CDK Inhibitors for the Treatment of Advanced and Resistant Cancers

On August 5, 2020 ARC Therapeutics, a development-stage pharmaceutical company developing small molecule inhibitors of cyclin-dependent kinases (CDKs) for the treatment of advanced and resistant cancers,reported that launched with a $6 million financing led by founding investor Eshelman Ventures LLC (Press release, ARC Therapeutics, AUG 5, 2020, View Source [SID1234562961]). With this financing, ARC Therapeutics has executed an exclusive license agreement with G1 Therapeutics for its preclinical CDK2 inhibitor program and will utilize remaining proceeds to advance this program into the clinic.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Uncontrolled cellular proliferation is a hallmark of cancer and is commonly driven by dysregulated kinase activity of specific CDK family members. Recent advances in cancer treatment using CDK inhibition have focused on targeting CDK4/6, key mediators of cell cycle progression. While this therapeutic approach has provided significant clinical benefit to patients with ER+/HER2- metastatic breast cancer, many tumors activate other CDK family members to drive uncontrolled proliferation. As a result, primary resistance has limited the broad clinical utility of CDK4/6 inhibitors. Those that do respond inevitably develop acquired resistance, resulting in tumor progression and limiting the drug’s effectiveness.

"The clinical success of CDK4/6 inhibitors demonstrates the practice-changing outcomes that can be achieved by therapeutically targeting specific CDK family members," said Patrick Roberts, Ph.D., Pharm.D., Chief Executive Officer and Co-Founder of ARC Therapeutics. "CDK2 is a known driver of abnormal cancer cell proliferation and is an important therapeutic target of unmet need. Our team is excited to apply its knowledge and expertise in developing potent and selective CDK inhibitors toward the development of a CDK2 inhibitor that has significant promise to advance the current standard of care for people living with cancer."

Scientific Approach

With an initial focus on developing a novel, potent, and selective inhibitor of CDK2 to treat patients whose tumors are insensitive to CDK4/6 inhibition, the founding scientific team at ARC Therapeutic is applying rational design and stringent screening criteria to select a candidate CDK2 inhibitor.

"Historical efforts to target CDK2 have been unsuccessful due to an inability to design or identify potent and selective CDK2 inhibitors," said Jay Strum, Ph.D., Chief Scientific Officer and Co-Founder of ARC Therapeutics. "The rational design approach we used to develop inhibitors selective for CDK4/6 versus CDK2 at G1 Therapeutics led to a keen understanding of key structural features within the CDK2 binding pocket that can be exploited to develop a potent and selective CDK2 inhibitor. At ARC Therapeutics, we now have an incredible opportunity to effectively treat patients with advanced and resistant cancers."

ARC Therapeutics entered into an exclusive license for the IP covering G1 Therapeutics’ preclinical CDK2 inhibitor program. Under the terms of the agreement, G1 Therapeutics received an upfront payment and equity in ARC Therapeutics.

Founding Team

ARC Therapeutics was founded by a group of experts with robust drug design, discovery, and development experience. As senior members of the scientific team that successfully identified and advanced three oncology compounds into the clinic at G1 Therapeutics, including a first-in-class myelopreservation therapy, a potential best-in-class differentiated oral CDK4/6 inhibitor and an oral selective estrogen receptor degrader (SERD), the team will apply its unique, multidisciplinary expertise and knowledge to pursue novel cancer treatments and drive programs in an expeditious manner.

"This team has an ideal combination of complementary experience and expertise to select the best compounds and bring them to the clinic," said Fred Eshelman, Pharm.D., co-founder and chairman of ARC Therapeutics and founder of Eshelman Ventures LLC. "I am confident in this team’s ability to successfully discover and develop inhibitors of CDK proteins and realize the company’s mission of improving the lives of patients with advanced and resistant cancers."